Palisade Bio (PALI) Short Interest Ratio & Short Volume

Short interest is the volume of Palisade Bio shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 34,500 shares of PALI short. 4.12% of Palisade Bio's shares are currently sold short. Learn More on Palisade Bio's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.12% of Palisade Bio's floating shares are currently sold short.

Palisade Bio saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 34,500 shares, an increase of 1,816.7% from the previous total of 1,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Palisade Bio currently has issued a total of 850,000 shares. Some of Palisade Bio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Palisade Bio currently has a public float of 836,500 shares.

4.12% of Palisade Bio's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Palisade Bio: Fresh Tracks Therapeutics, Inc. (0.17%), Finch Therapeutics Group, Inc. (1.96%), TRACON Pharmaceuticals, Inc. (1.16%), Creative Medical Technology Holdings, Inc. (1.76%), Titan Pharmaceuticals, Inc. (1.72%), Plus Therapeutics, Inc. (1.10%), Avalon GloboCare Corp. (2.84%), Gamida Cell Ltd. (7.11%), Genetic Technologies Limited (0.41%), Organovo Holdings, Inc. (1.49%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

Short selling PALI is an investing strategy that aims to generate trading profit from Palisade Bio as its price is falling. PALI shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Palisade Bio occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PALI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PALI, twice per month. The most recent reporting period available is April, 15 2024.